TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05533970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided high fascia iliaca compartment block
Description: H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided high fascia iliaca compartment block
Description: H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided high fascia iliaca compartment block
Description: H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
Study: NCT06531317

Intervention type: DEVICE
Intervention: transcranial Direct Current Stimulation
Description: The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography
Description: 64-channel active-electrode EEG with impedances kept \~5KOhm
Study: NCT05052398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSP NEURO SERUM
Description: PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PSP NEURO SERUM
Description: Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
Study: NCT05976672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRSS (Peer Recovery Support Specialist)
Description: Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
Study: NCT05197088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 1 week of tamsulosin
Study: NCT06434662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride liposome
Description: Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
Study: NCT06546904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence empowers anesthesia with ultrasound assistance
Description: Artificial intelligence empowers anesthesia with ultrasound assistance
Study: NCT05361317

Intervention type: DEVICE
Group type: OTHER
Intervention: Nexis® PECA Bunion device
Description: Hallux valgus correction with percutaneous chevron and Akin osteotomy.
Study: NCT06404632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lev-g
Description: Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
Study: NCT01089205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT06457698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-puncture TMJ arthrocentesis under local anaesthesia
Description: The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Double-puncture TMJ arthrocentesis under local anaesthesia
Description: The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
Study: NCT06276166

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05270655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention
Description: Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
Study: NCT05071014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 200mg/dose delivered by IV infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided cryoablation
Description: Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
Study: NCT05036967

Intervention type: DRUG
Intervention: HF medication
Description: Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
Study: NCT06267079

Intervention type: OTHER
Group type: OTHER
Intervention: core stability exercise
Description: Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).

Intervention type: OTHER
Group type: OTHER
Intervention: core stability exercise
Description: Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
Study: NCT00930995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: 16mg po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT04710706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy insertion technique used during procedure
Description: Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy insertion technique used during procedure
Description: Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
Study: NCT06370156

Intervention type: DRUG
Intervention: Adalimumab
Description: To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.

Intervention type: DRUG
Intervention: Adalimumab
Description: To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.

Intervention type: DRUG
Intervention: Adalimumab
Description: To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
Study: NCT06198244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation(TENS)
Description: Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
Study: NCT05503043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients are received equal volumes of saline intravenously until the end of the surgery
Study: NCT05728528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
Description: combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Description: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Study: NCT05129618

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MHS 1031
Description: prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
Study: NCT04658511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
Study: NCT06198244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Treatment
Description: In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
Study: NCT06170697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, iv, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80-100mg/m2, iv, q3w, 2-3 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2, iv, q1w, 5-7 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: 30mg/m2, iv, q3w, 2-3 cycles in total
Study: NCT06085924

Intervention type: DRUG
Intervention: SoC
Description: COVID-19 treatment as per government guidance

Intervention type: OTHER
Intervention: Disease description
Description: No intervention
Study: NCT06170697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 25-30 mg/m2, iv, q1w, 5-7 cycles in total

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
Study: NCT06196489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted vaping cessation intervention
Description: Behavioral intervention for vaping cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted vaping cessation intervention
Description: Behavioral intervention for vaping cessation
Study: NCT05466045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil application in hemodialysis patients with pruritus
Description: Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline application in hemodialysis patients with pruritus
Description: Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
Study: NCT04660110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPT with Dihydroartemisinin Piperaquine
Description: A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
Study: NCT05723172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tACS
Description: 40 mins tACS for 10 consecutive daily sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: 40 mins sham tACS for 10 consecutive daily sessions
Study: NCT05107700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stay at altitude 2500 m above sea level (high altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stay at altitude 2500 m above sea level (high altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stay at altitude 470 m above sea level (low altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stay at altitude 470 m above sea level (low altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
Study: NCT04855019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder periarticular injection, suprascapular and axillary nerve block
Description: In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder periarticular injection, suprascapular and axillary nerve block
Description: In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance.
Study: NCT05169411

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure
Description: The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure
Description: The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine protein
Description: Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
Study: NCT04942782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbopelvic stabilization exercises
Description: the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise
Description: the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance